Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has been assigned a consensus recommendation of “Buy” from the nine ratings firms that are covering the company, MarketBeat reports. Nine research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have covered the stock in the last year is $49.00.
PLRX has been the topic of a number of research analyst reports. Royal Bank of Canada boosted their price target on Pliant Therapeutics from $50.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 5th. HC Wainwright restated a “buy” rating and set a $48.00 price target on shares of Pliant Therapeutics in a research note on Wednesday, February 28th. Finally, Needham & Company LLC restated a “buy” rating and set a $38.00 price target on shares of Pliant Therapeutics in a research note on Wednesday, April 10th.
View Our Latest Analysis on Pliant Therapeutics
Institutional Investors Weigh In On Pliant Therapeutics
Pliant Therapeutics Stock Performance
Shares of Pliant Therapeutics stock opened at $12.52 on Wednesday. The company has a market capitalization of $754.20 million, a PE ratio of -4.49 and a beta of 1.12. The company has a debt-to-equity ratio of 0.02, a quick ratio of 17.72 and a current ratio of 17.72. The company has a 50-day simple moving average of $15.15 and a two-hundred day simple moving average of $15.67. Pliant Therapeutics has a one year low of $12.00 and a one year high of $30.85.
Pliant Therapeutics Company Profile
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
See Also
- Five stocks we like better than Pliant Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Comprehensive Analysis of PayPal Stock
- What is a Death Cross in Stocks?
- Intuitive Surgical Stock Can Trend Much Higher This Year
- Quiet Period Expirations Explained
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.